(198al) Novel Glucosylceramide Synthase Inhibitor Based Prodrug Copolymer Micelles for Delivery of Doxorubicin

In order to improve the efficacy of chemotherapy for cancers, we have developed a novel prodrug micellar formulation to co-deliver ceramide-generating anticancer agents and ceramide degradation inhibitor (PPMP). The prodrug nanocarrier is based on a well-defined POEG-b-PPPMP diblock copolymer. The hydrophilic block of POEG-b-PPPMP is POEG, and the hydrophobic block is composed of a number of PPMP units, which could work synergistically with loaded anticancer drugs. POEG-b-PPPMP was readily synthesized via a one-step reversible addition-fragment transfer (RAFT) polymerization from a PPMP monomer. The newly synthesized polymers were self-assembled into micelles and served as a carrier for several hydrophobic anticancer drugs including DOX, PTX and ceramide. POEG-b-PPPMP prodrug polymer formed uniform micelles with a size of ~100 nm and exhibited intrinsic antitumor activity in vitro and in vivo. DOX-loaded POEG-b-PPPMP micelles exhibited an excellent stability of 42 days at 4 °C. In addition, POEG-b-PPPMP prodrug polymer was comparable to free PPMP in enhancing the production of ceramide as well as down-regulating the mRNA expression of GCS. Moreover, DOX loaded in POEG-b-PPPMP micelles showed higher levels of cytotoxicity than DOX loaded in a pharmacologically inert polymer (POEG-b-POM) and Doxil formulation in several tumor cell lines. Consistently, in a 4T1.2 murine breast cancer model, the tumor inhibition followed the order of DOX/POEG-b-PPPMP > DOX/POEG-b-POM ≥ Doxil > POEG-b-PPPMP> POEG-b-POM. Our data suggest that POEG-b-PPPMP micelles are a promising dual-functional carrier that warrants more studies in the future.